241 related articles for article (PubMed ID: 21315418)
1. Deletion of the inhibitor of growth 4 (ING4) tumor suppressor gene is prevalent in human epidermal growth factor 2 (HER2)-positive breast cancer.
Tapia C; Zlobec I; Schneider S; Kilic E; Güth U; Bubendorf L; Kim S
Hum Pathol; 2011 Jul; 42(7):983-90. PubMed ID: 21315418
[TBL] [Abstract][Full Text] [Related]
2. ING4 Expression Landscape and Association With Clinicopathologic Characteristics in Breast Cancer.
Shatnawi A; Ayoub NM; Alkhalifa AE
Clin Breast Cancer; 2021 Aug; 21(4):e319-e331. PubMed ID: 33334698
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
4. Differential cellular localization of CELSR2 and ING4 and correlations with hormone receptor status in breast cancer.
Jiang L; Zhang X; Xiang C; Geradts J; Wei Q; Liang Y; Huang H; Xu JF
Histol Histopathol; 2018 Aug; 33(8):835-842. PubMed ID: 29489009
[TBL] [Abstract][Full Text] [Related]
5. Early and Locally Advanced Metaplastic Breast Cancer: Presentation and Survival by Receptor Status in Surveillance, Epidemiology, and End Results (SEER) 2010-2014.
Schroeder MC; Rastogi P; Geyer CE; Miller LD; Thomas A
Oncologist; 2018 Apr; 23(4):481-488. PubMed ID: 29330212
[TBL] [Abstract][Full Text] [Related]
6. Aberrant methylation of RASSF1A is associated with poor survival in Tunisian breast cancer patients.
Karray-Chouayekh S; Trifa F; Khabir A; Boujelbane N; Sellami-Boudawara T; Daoud J; Frikha M; Jlidi R; Gargouri A; Mokdad-Gargouri R
J Cancer Res Clin Oncol; 2010 Feb; 136(2):203-10. PubMed ID: 19657672
[TBL] [Abstract][Full Text] [Related]
7. Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.
Frogne T; Laenkholm AV; Lyng MB; Henriksen KL; Lykkesfeldt AE
Breast Cancer Res; 2009; 11(1):R11. PubMed ID: 19239686
[TBL] [Abstract][Full Text] [Related]
8. Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study.
Vohra P; Buelow B; Chen YY; Serrano M; Vohra MS; Berry A; Ljung BM
Cancer Cytopathol; 2016 Nov; 124(11):828-835. PubMed ID: 27315045
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of estrogen, progesterone and HER2 receptors' status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia.
Al-Saleh K; Salah T; Arafah M; Husain S; Al-Rikabi A; Abd El-Aziz N
PLoS One; 2021; 16(3):e0247802. PubMed ID: 33667252
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of a novel cell cycle regulator ecdysoneless in breast cancer: a marker of poor prognosis in HER2/neu-overexpressing breast cancer patients.
Zhao X; Mirza S; Alshareeda A; Zhang Y; Gurumurthy CB; Bele A; Kim JH; Mohibi S; Goswami M; Lele SM; West W; Qiu F; Ellis IO; Rakha EA; Green AR; Band H; Band V
Breast Cancer Res Treat; 2012 Jul; 134(1):171-80. PubMed ID: 22270930
[TBL] [Abstract][Full Text] [Related]
11. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
12. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
[TBL] [Abstract][Full Text] [Related]
13. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
[TBL] [Abstract][Full Text] [Related]
14. Landscape of HER2-low breast cancer: Insights from a six-year study on prevalence and clinicopathological characteristics.
Khalil MA; Habibian L; Martin C; Semaan K; Khaddage A; El Kassis N; Kesserouani C; Kourie HR; Atallah D
Ann Diagn Pathol; 2024 Oct; 72():152326. PubMed ID: 38759564
[TBL] [Abstract][Full Text] [Related]
15. Expression patterns of ER, HER2, and NM23-H1 in breast cancer patients with different menopausal status: correlations with metastasis.
Dong SW; Wang L; Sui J; Deng XY; Chen XD; Zhang ZW; Liu X; Liu ZM; Zhang JH; Yang QS; Jia YF; Song X
Mol Diagn Ther; 2011 Aug; 15(4):211-9. PubMed ID: 21913743
[TBL] [Abstract][Full Text] [Related]
16. Expression profiling of breast tumors based on human epidermal growth factor receptor 2 status defines migration-related genes.
Cuadros M; Cano C; López FJ; López-Castro R; Concha A
Pathobiology; 2013; 80(1):32-40. PubMed ID: 22832278
[TBL] [Abstract][Full Text] [Related]
17. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
[TBL] [Abstract][Full Text] [Related]
18. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
19. The mitochondrial transporter SLC25A43 is frequently deleted and may influence cell proliferation in HER2-positive breast tumors.
Tina E; Lindqvist BM; Gabrielson M; Lubovac Z; Wegman P; Wingren S
BMC Cancer; 2012 Aug; 12():350. PubMed ID: 22883974
[TBL] [Abstract][Full Text] [Related]
20. Delay to formalin fixation effect on breast biomarkers.
Khoury T; Sait S; Hwang H; Chandrasekhar R; Wilding G; Tan D; Kulkarni S
Mod Pathol; 2009 Nov; 22(11):1457-67. PubMed ID: 19734848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
